2026 Patient Research Report
The DTP Imperative: Building Direct-to-Patient Programs That Exceed Patient Expectations
PHIL surveyed 1,049 U.S. patients in March 2026 to reveal their most pressing expectations for today's direct-to-patient programs, and what the data means for pharma leaders.
Download Report →Patient Expectations Have Changed. This Research Reveals What Patients Want from Pharma's Direct-to-Patient Programs.
PHIL surveyed 1,049 U.S. patients who have received a prescription medication in the past five years. The findings highlight the most pressing needs, challenges, and preferences of today's patients, and what the next generation of DTP programs must deliver.
What's Inside
The Awareness-to-Access Gap
How access and affordability barriers are creating drop-off between patient interest and first fills, and where DTP programs can meaningfully bridge the gap.
The Pricing Imperative
Affordable, transparent pricing is pharma's single biggest lever for driving DTP adoption, starts, and long-term adherence.
High Standards for Experience
Patients expect DTP programs to mirror the seamless digital experience they get everywhere else, and brand-led experiences are key for driving trust.
“Today, consumer-grade direct-to-patient programs that are custom-built to exceed patient expectations are the industry's most powerful strategic lever for improving patient outcomes while driving commercial performance at scale.”
Deepak ThomasCEO & Founder, PHIL Inc.
See What's Possible
Ready to Build a Best-in-Class DTP Program?
PHIL helps leading pharma brands launch custom direct-to-patient programs that exceed patient expectations and drive commercial impact.
Book Demo →FAQs About the Research
How was the survey collected?
PHIL surveyed 1,049 U.S. patients in March 2026. An independent third-party research firm collected the sample, and responses were 100% anonymous. All respondents have received a prescription medication in the past five years in the United States.
What does the research cover?
The report uncovers patients' most pressing expectations for today's direct-to-patient programs, from the awareness-to-access gap and the role of affordable, transparent pricing to patients' high standards for digital, brand-led experiences, and what the data reveals for pharma leaders.
Who is the research relevant for?
Pharmaceutical and biotechnology professionals that oversee access and commercial strategy, including leadership, patient access, commercial, brand, and innovation teams.
How do I access the research?
Access the research by filling out the form on this page.
